97 related articles for article (PubMed ID: 35467760)
1. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer.
Guenther M; Boeck S; Heinemann V; Werner J; Engel J; Ormanns S
Int J Cancer; 2022 Sep; 151(6):914-919. PubMed ID: 35467760
[TBL] [Abstract][Full Text] [Related]
2. IPMN-associated pancreatic cancer: Survival, prognostic staging and impact of adjuvant chemotherapy.
Kaiser J; Scheifele C; Hinz U; Leonhardt CS; Hank T; Koenig AK; Tjaden C; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jun; 48(6):1309-1320. PubMed ID: 34920899
[TBL] [Abstract][Full Text] [Related]
3. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
4. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity.
Yabusaki N; Fujii T; Yamada S; Murotani K; Sugimoto H; Kanda M; Nakayama G; Koike M; Fujiwara M; Kodera Y
Medicine (Baltimore); 2016 Jul; 95(29):e4282. PubMed ID: 27442667
[TBL] [Abstract][Full Text] [Related]
5. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8
Hamura R; Haruki K; Fujiwara Y; Tsunematsu M; Shirai Y; Furukawa K; Onda S; Gocho T; Shiba H; Uwagawa T; Usuba T; Fujioka S; Okamoto T; Ikegami T
Langenbecks Arch Surg; 2022 Dec; 407(8):3437-3446. PubMed ID: 36173461
[TBL] [Abstract][Full Text] [Related]
6. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Shi J; Li X; Wu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
[TBL] [Abstract][Full Text] [Related]
7. Early versus delayed initiation of adjuvant treatment for pancreatic cancer.
Kim HW; Lee JC; Lee J; Kim JW; Kim J; Hwang JH
PLoS One; 2017; 12(3):e0173960. PubMed ID: 28301556
[TBL] [Abstract][Full Text] [Related]
8. Does adjuvant therapy improve overall survival for stage IA/B pancreatic adenocarcinoma?
Ostapoff KT; Gabriel E; Attwood K; Kuvshinoff BW; Nurkin SJ; Hochwald SN
HPB (Oxford); 2017 Jul; 19(7):587-594. PubMed ID: 28433254
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
[TBL] [Abstract][Full Text] [Related]
10. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study.
Liang L; Ding Y; Yu Y; Liu K; Rao S; Ge Y; Zeng M
BMC Med Imaging; 2021 Apr; 21(1):75. PubMed ID: 33902469
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
12. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma.
Hu H; Zhu Y; Pu N; Burkhart RA; Burns W; Laheru D; Zheng L; He J; Goggins MG; Yu J
J Am Coll Surg; 2020 Nov; 231(5):527-535.e14. PubMed ID: 32659497
[TBL] [Abstract][Full Text] [Related]
13. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
14. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
15. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
16. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
17. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
Hwang JH; Voortman J; Giovannetti E; Steinberg SM; Leon LG; Kim YT; Funel N; Park JK; Kim MA; Kang GH; Kim SW; Del Chiaro M; Peters GJ; Giaccone G
PLoS One; 2010 May; 5(5):e10630. PubMed ID: 20498843
[TBL] [Abstract][Full Text] [Related]
18. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
19. Refined prognostic staging for resected pancreatic cancer by modified stage grouping and addition of tumour grade.
König AK; Gros H; Hinz U; Hank T; Kaiser J; Hackert T; Bergmann F; Büchler MW; Strobel O
Eur J Surg Oncol; 2022 Jan; 48(1):113-120. PubMed ID: 34344573
[TBL] [Abstract][Full Text] [Related]
20. Completion of adjuvant therapy in patients with resected pancreatic cancer.
DePeralta DK; Ogami T; Zhou JM; Schell MJ; Powers BD; Hodul PJ; Malafa MP; Fleming JB
HPB (Oxford); 2020 Feb; 22(2):241-248. PubMed ID: 31563326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
